TL;DR

Slingshot AI is withdrawing its therapy chatbot app Ash from the United Kingdom this week, citing concerns that it may violate the country’s medical device regulations. The move highlights the regulatory uncertainty facing AI mental health products in the UK market.

Regulatory Roadblock

Slingshot AI, which has raised $93 million from investors including Andreessen Horowitz, announced it will withdraw its therapy chatbot Ash from the UK market effective 23 January 2026. The decision comes amid concerns that the app may run afoul of the country’s medical device regulations.

In an email to users, Slingshot CEO Daniel Reid Cahn explained the reasoning: “There isn’t a clear regulatory pathway for wellbeing products like ours—and without that clarity, we can’t operate with confidence.” The company has indicated it is in conversations with the government seeking a remedy.

The Broader Context

Slingshot has been among the most aggressive companies pushing large language model-based mental health products to consumers. This comes amid broader concerns within the healthcare sector about whether generative AI chatbots are suitable—or safe—for people with mental health issues.

The UK’s medical device regulations require products making therapeutic claims to undergo rigorous approval processes. The line between “wellbeing” products and medical devices has become increasingly blurred as AI applications become more sophisticated in their ability to provide what appears to be therapeutic support.

Implications for UK Market

The withdrawal represents a significant moment for AI mental health applications in the UK. It demonstrates that even well-funded startups face substantial barriers when regulatory frameworks haven’t kept pace with technological development.

For UK businesses developing or deploying AI applications in health-adjacent areas, the Slingshot case underscores the importance of engaging with regulators early and ensuring clear understanding of how products will be classified.

Looking Forward

The situation highlights a growing tension across regulated markets: AI capabilities are advancing faster than regulatory frameworks can adapt. Companies positioning products as “wellbeing” tools rather than medical devices may find this distinction increasingly difficult to maintain as AI becomes more capable of providing substantive mental health support.

The outcome of Slingshot’s conversations with UK regulators could set important precedents for other AI mental health applications seeking to operate in the market.